http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Jung, Sung-Hoon,Lee, Je-Jung,Kim, Jin Seok,Min, Chang-Ki,Kim, Kihyun,Choi, Yunsuk,Eom, Hyeon-Seok,Joo, Young Don,Kim, Sung-Hyun,Kwak, Jae-Yong,Kang, Hye Jin,Lee, Jae Hoon,Lee, Ho Sup,Mun, Yeung-Chul,M Elsevier 2018 Biology of blood and marrow transplantation Vol.24 No.5
<P><B>Abstract</B></P> <P>This prospective study evaluated the efficacy and toxicity of intravenous busulfan and melphalan as a conditioning regimen for autologous stem cell transplantation (ASCT) in patients with multiple myeloma (MM). A total of 99 patients with MM, enrolled between January 2013 and March 2016, received intravenous busulfan (9.6 mg/kg) and melphalan (140 mg/m<SUP>2</SUP>) before ASCT. The median time to transplant was 6.2 months, and 90 (90.9%) patients underwent ASCT within 12 months of the diagnosis. The overall response rate after ASCT was 94.0%, including 43.5% with a stringent complete response/complete response, 27.3% with very good partial response, and 23.2% with partial response. The most common severe nonhematologic toxicity (grade 3 to 4) was infection (26.3%) and stomatitis (15.2%). Three (3.2%) patients developed veno-occlusive disease. No treatment-related mortality was observed. After a median follow-up of 26.1 months, the median progression-free survival was 27.2 months (range, 13.0 to 41.4 months) and median overall survival was not reached. In conclusion, a conditioning regimen of intravenous busulfan and melphalan was effective and tolerable.</P> <P> ClinicalTrials.gov. number: NCT01923935</P> <P><B>Highlights</B></P> <P> <UL> <LI> Intravenous busulfex and melphalan conditioning regimen leads to high-quality response after autologous stem cell transplantation in patients with multiple myeloma. </LI> <LI> Intravenous busulfex and melphalan was a well-tolerated conditioning regimen with a low incidence of veno-occlusive disease and transplant-related mortality. </LI> </UL> </P>
IEEE-1394 직렬 버스를 이용한 화상 전화 시스템의 구현
강성일(Sung-Il Kang),편기현(Kihyun Pyun),이충훈(Choong-Hoon Lee),이흥규(Heung-Kyu Lee),강성봉(Sung-Bong Kang) 한국정보과학회 1999 정보과학회 컴퓨팅의 실제 논문지 Vol.5 No.3
최근 IEEE-1394 직렬 버스는 컴퓨터와 가전기기가 결합된 차세대 가정 자동화를 위한 통신 기술로 주목받고 있다. 본 논문은 이러한 1394 버스에서 사용할 수 있는 PC용 화상 전화 시스템(VPS) 구현에 대한 내용을 기술한 것이다. 개발된 화상 전화 시스템은 기본적으로 고품질의 오디오와 비디오를 실시간으로 전송할 수 있으며 온라인 문자 정보를 교환을 위한 채팅 기능과 사용중 문서나 이미지를 전달할 수 있는 고속 파일 전송 기능을 부가적으로 제공하고 있다. VPS는 내부적으로 실시간 처리 기능이 없는 일반 PC 운영체제에서 실시간 전송이 가능한 1394 버스를 사용할 때 컴퓨터 시스템이 불안정해지는 문제를 피하고 손실에 민감한 오디오를 보호하기 위하여 부하에 따라 비디오 처리를 조절하는 비대칭적 버퍼제어 기법을 사용하고 있다. In the recent, the IEEE-1394 serial bus is getting attentions as a communication technology for the next-generation home automation that computers and consumer electronics are combined. This paper describes the implementation of a Video Phone System(VPS) for PC operating on the 1394 bus. The developed VPS can basically transmit high-quality audio and video in real-time, and also provides a chatting function for exchanging the text information on-line and a fast file transfer function for delivery of documents or images in use. To avoid the problem that the computer using the real-time 1394 bus can be unstable under the general operating system without the real-time processing capability, the VPS internally uses an asymmetric buffer control scheme that protects audio sensitive to the loss and controls the processing of video according to the internal load of a computer system.
Park, Sung-Soo,Kim, Kihyun,Kim, Seok-Jin,Lee, Jae Hoon,Yoon, Sung Soo,Mun, Yeung Chul,Lee, Je-Jung,Eom, Hyeon-Seok,Kim, Jin Seok,Min, Chang-Ki AMERICAN SOCIETY FOR BLOOD AND MARROW 2019 BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION Vol.25 No.7
<P><B>ABSTRACT</B></P> <P>A phase I/II trial was conducted to explore the safety and activity of the addition of bortezomib on days -6, -3, and +1 relative to the day of autologous stem cell transplantation (ASCT) to a conditioning regimen with busulfan and melphalan (BuMel; 3.2 mg/kg/day busulfan on days -5 to -3 and 140 mg/m<SUP>2</SUP>/day melphalan on day -2) in patients with multiple myeloma (MM) following bortezomib-based induction chemotherapy. In phase I, doses of bortezomib (.7, 1.0, and 1.3 mg/m<SUP>2</SUP>) with BuMel were administered to groups of 3 patients each. No dose-limiting toxicities were observed. The maximum tolerated dose of bortezomib was 1.3 mg/m<SUP>2</SUP>/day. A subsequent cohort with 41 patients was analyzed in a phase II trial to identify safety and efficacy. The phase II trial showed a 75% response rate, including very good partial response (VGPR) or better, and a 55% rate of complete response (CR) at 3 months; For post-transplantation best response, an 83% rate of VGPR or better (68% CR) was observed. With a median follow-up of 31.4 months, the median progression-free survival (PFS) was 26.8 months. The probability of 2 year-PFS was 56.5%, and median overall survival (OS) could not calculated. Specifically, high-risk cytogenetics were associated with adverse survival outcomes compared with standard-risk cytogenetics (median PFS, 12.2 months versus 35.7 months, <I>P</I> = .039; median OS, 26.7 months versus 73.3 months; <I>P</I> = .086). With a median of 11 days to neutrophil engraftment and 10 days for platelet engraftment, no graft failure or delayed engrafting were observed. The most common grade 3 or severe nonhematologic adverse events included neutropenic fever (73.2%) and stomatitis (14.6%). Except for 3 patients with transplantation-related mortality due to sepsis, other adverse events were manageable. These findings demonstrate that bortezomib is safe and has a potential role in conditioning regimens in combination with BuMel for patients with transplantation-eligible MM.</P> <P><B>Highlights</B></P> <P> <UL> <LI> Bortezomib, busulfan, and melphalan conditioning for autologous stem cell transplantation (ASCT) in multiple myeloma was feasible in this phase I/II study. </LI> <LI> After ASCT, 83% of patients achieved very good partial response and 68% achieved complete response. </LI> <LI> Despite the short duration of follow-up, progression-free survival was acceptable (median, 26.8 months). </LI> <LI> Manageable toxicity profiles were observed. </LI> </UL> </P>